Diligence memo · auto-generated · as of July 2, 2026

Co-Diagnostics, Inc.

Co-Diagnostics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Co-Diagnostics, Inc. operates in Biotechnology, based in SALT LAKE CITY.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Co-Diagnostics, Inc. has raised $47M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $47M on 2021-12-31.

Most recent recorded round closed around 2021-12-31.

Valuation (modeled)modeled

Provath models Co-Diagnostics, Inc. at approximately $1.1B (range $144M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.55× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Issuer reports $25M–$100M revenue while modeled below niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 61 months.

Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 62.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).

Modeled value ranks above 90% of those peers.

Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.